3XB0 Stock Chart & Stats
€3.86
€0.00(0.00%)
At close: 4:00 PM EDT
€3.86
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.86 - €4.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.04M
Enterprise Value-€1.21
Total Cash (Recent Filing)€6.47M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.88
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding2,291,056
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.83
Revenue Forecast (FY)€2.56M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~80% gross margins indicate structurally favorable unit economics for reported revenue, giving the company a durable advantage once scale grows. High product/royalty margins lower the revenue required to cover fixed R&D and SG&A, improving long-term path to profitability if top-line expands.
Conservative Capital StructureNo debt reduces interest burden and financial distress risk, preserving flexibility to fund R&D via equity, partnerships, or royalties. A debt-free balance sheet is a durable strength for a development-stage biotech facing lumpy funding needs and regulatory timelines.
Pipeline Scientific Progress & Diversified RevenueASCO translational data supporting DNase I represents structural pipeline progress that can enable clinical advancement, partnerships, or licensing. Combined with continuing royalty revenue from legacy PolyXen, this creates multiple durable value pathways beyond one-time financing events.
Bears Say
Deep Negative ProfitabilityA ~-76% net margin and negative EBIT/EBITDA show the company cannot yet cover operating costs with current revenues. Unless pipeline assets translate into meaningful recurring revenue or cost structure tightens long-term, sustained losses threaten equity value and require ongoing funding.
Ongoing Cash BurnNegative operating and free cash flow of roughly -$2.3M TTM indicate continued cash burn despite improvement. This persistent outflow forces reliance on external financing or partnerships; recurring cash deficits constrain long-term R&D planning and increase dilution risk until operating cash flow turns positive.
Equity Decline / Resource ConstraintsA marked drop in shareholders' equity signals prior capital drawdown or dilution, highlighting funding strain. Combined with a very small internal headcount and development-stage profile, this suggests limited internal capacity and higher dependence on partners, which can slow execution and commercialization.
Xenetic Biosciences News
3XB0 FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was €3.86 and its highest was €4.00 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is €5.04M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Nov 06, 2026 which is in 89 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Aug 07, 2026. The company reported -€0.35 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -€0.35 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in DE:3XB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.